3,4-methylenedioxymethamphetamine
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01616407 | Aug → Dec 2012 | CGF1 | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT06884514 | Apr 2025 → May 2026 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT05277636 | Oct 2022 → Jan 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT04847206 | Dec 2021 → Jun 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT04516902 | Jan 2021 → Aug 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT03790618 | Jun 2016 → Aug 2018 | — | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT01465685 | Dec 2011 → Dec 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01386177 | Jul 2011 → Jan 2012 | amphetamine abuse, mood disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01136278 | Jul → Dec 2010 | amphetamine abuse, mood disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00990067 | Nov 2009 → May 2010 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07288151 | Jul 2026 → Jan 2030 expected | post-traumatic stress disorder | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT05783817 | Sep 2025 → Dec 2026 expected | obsessive-compulsive disorder | Carolyn Rodriguez | Recruiting | No outcome recorded |
| Phase 2 | NCT06954025 | May 2025 → Dec 2026 expected | post-traumatic stress disorder | ARQ National Psychotrauma Centre | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05790239 | Mar 2025 → Mar 2026 overdue | post-traumatic stress disorder | Stephen Robert Marder | Recruiting | No outcome recorded |
| Phase 2 | NCT04264026 | Jul 2021 → May 2025 | combat disorder, post-traumatic stress disorder | VA Loma Linda Health Care System | Completed | No outcome recorded |
| Phase 2 | NCT00252174 | Feb 2007 → Dec 2010 | anxiety disorder, cancer | Brigham and Women's Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00353938 | Sep 2006 → Sep 2009 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06117306 | Oct 2024 → Aug 2027 expected | post-traumatic stress disorder | Healing Breakthrough | Recruiting | No outcome recorded |
| Phase 3 | NCT05979844 | Oct 2023 → Nov 2025 | post-traumatic stress disorder | Dr. Leslie Morland | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01270672 | Jan → May 2011 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT06081179 Comparator | Oct 2023 → Sep 2025 | — | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT05523401 Comparator | Aug 2023 → Oct 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT05488171 Comparator | Dec 2021 → Jul 2022 | substance-related disorder | Germans Trias i Pujol Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02232789 Comparator | Sep → Dec 2014 | substance-related disorder | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 2 | NCT07301632 Comparator | Jan 2026 → Dec 2027 expected | neuropathy, painful | Unity Health Toronto | Recruiting | No outcome recorded |
| — | NCT01053403 Comparator | Apr → Dec 2010 | substance withdrawal syndrome | California Pacific Medical Center Research Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4 methylenedioxymethamphetamine | “The prosocial compound ± 3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has shown promise as an adjunct to psychotherapy in the treatment of...” PMID 38279662 ↗ Jan 202427“Drug: 3,4-methylenedioxymethamphetamine (MDMA) Session 1: 80 mg MDMA HCl followed by a supplemental dose of 40 mg Session 2: 120 mg MDMA HCl followed by a supplemental dose of 60 mg” NCT06954025 ↗ “3,4-methylenedioxymethamphetamine (MDMA) is a drug that can produce effects uniquely suited to reducing anxiety for people with anxiety arising from a cancer diagnosis.” NCT00252174 ↗ “MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.” NCT05783817 ↗ |
| Known as | MDMA | “The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4-methylenedioxymethamphetamine...” PMID 31572236 ↗ Sep 20197“The prosocial compound ± 3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has shown promise as an adjunct to psychotherapy in the treatment of...” PMID 38279662 ↗ Jan 2024 “One promising path is the role of MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy in augmenting the relational impact of established therapeutic interventions such as bCBCT.” PMID 38994348 ↗ May 2024 “Drug: 3,4-methylenedioxymethamphetamine (MDMA) Session 1: 80 mg MDMA HCl followed by a supplemental dose of 40 mg Session 2: 120 mg MDMA HCl followed by a supplemental dose of 60 mg” NCT06954025 ↗ “3,4-methylenedioxymethamphetamine (MDMA) is a drug that can produce effects uniquely suited to reducing anxiety for people with anxiety arising from a cancer diagnosis.” NCT00252174 ↗ “The 5-HT and oxytocin releaser 3,4-methylenedioxymethamphetamine (MDMA) reliably induces positive mood, euphoria, comfort, empathy, and feelings of trust.” NCT06884514 ↗ “3,4-methylenedioxymethamphetamine (MDMA)” NCT06117306 ↗ “MDMA” NCT07288151 ↗ |
| Known as | midomafetamine | “3,4-methylenedioxymethamphetamine (MDMA, midomafetamine)” PMID 36873994 ↗ Feb 2023 |
| Modality | Small molecule | “MDMA is an amphetamine derivative” PMID 38279662 ↗ Jan 2024 |
| Route | Oral | “Participants will receive an initial dose of 125 mg MDMA orally” NCT00353938 ↗ |